Multiple Myeloma Clinical Trial
Official title:
A Multicenter, Randomized, Comparative, Patient-blinded Study to Evaluate the Safety and Efficacy of G-CSF Alone Versus AMD3100 (240 µg/kg) Added to a G-CSF Mobilization Regimen in Adult Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkins Disease (HD) or Multiple Myeloma (MM) Who Have Previously Failed Stem Cell Collections or Collection Attempts
Verified date | February 2014 |
Source | Sanofi |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Federal Institute for Drugs and Medical Devices |
Study type | Interventional |
Some patients with multiple myeloma or lymphoma will need treatment with high dose
chemotherapy to treat their condition. This potent treatment will kill many of the
blood-forming cells in the bone marrow. The patient will therefore need these blood-forming
cells replaced after the chemotherapy treatment. This is done by collecting some of teh
patients own blood-forming stem cells before chemotherapy, storing them and then infusing
them into the patient after chemotherapy (in the same way as a blood transfusion is given).
The stem cells will then make their way unto the bone marrow and re-populate it. Having stem
cells collected and returned later is called an "Autologous Transplant".
In most patients these blood-forming stem cells (which normally live in the bone marrow) are
"mobilized" into the blood stream where they are then collected by a process called
apheresis (a bit like donating blood). This process of mobilization is not always
successful. In this study patients who did not collect enough stem cells in a previous cell
collection attempt to have an autologous stem cell transplant will participate. Patients
will be mobilized with G-CSF (current standard treatment to mobilize stem cells) and the
effect of adding AMD3100 to G-CSF will be studied by comparing outcomes in patients who get
G-CDF with placebo (non-active substance which looks like AMD3100) to patients who get G-CSF
with AMD3100.
AMD3100 is a member of a new class of medications called "chemokine inhibitors". The drug
triggers the movement of stem cells out of the bone marrow into the blood stream. In
previous studies with healthy volunteers and cancer patients, when AMD3100 and G-CSF were
used in combination, a greater number of stem cells were mobilized into the blood stream
than by using g-CSF alone.
The purposes of this study are to measure how many stem cells can be collected, the number
of days to collect those cells and the safety of a mobilization regimen of AMD3100 with
G-CSF compared to G-CSF with placebo. If enough cells are collected to have a transplant,
the study will also evaluate how well the cells grow when transplanted.
Status | Completed |
Enrollment | 5 |
Est. completion date | June 2009 |
Est. primary completion date | April 2008 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 78 Years |
Eligibility |
Inclusion Criteria: - Eligible to undergo autologous transplantation. - Diagnosis of NHL, HD or MM [patients with plasma cell leukemia or other leukemias including chronic lymphocytic leukemia (CLL), are excluded]. - In the last collection attempt prior to entry into this trial, the patient has failed to collect 0.8x10^6 cells/kg in at least 2 apheresis sessions or 2x10^6 cells/kg in 4 apheresis sessions using a mobilization regimen of chemotherapy, with or without G-CSF. - A minimum of a 7 day interval between last collection attempt and randomization. - Cardiac, pulmonary and renal function deemed clinically adequate to be able to undergo mobilization and transplant. - Performance status, Eastern Cooperative Oncology Group (ECOG) of 0 or 1 - = 21 days between the last cycle of chemotherapy and randomization (thalidomide, dexamethasone, and other corticosteroids, Rituxan® and Velcade® are not considered prior chemotherapy for the purpose of this study). - The patient has recovered from all acute toxic effects of prior chemotherapy. - WBC = 2.5x10^9/l. - Absolute neutrophil count = 1.5x10^9/l. - Platelet count = 75x10^9/l. - Adequate renal function as demonstrated by serum creatine = or equal to 2.2 mg/dl or creatinine clearance (24 hr urine collection)= 60 ml/min - Serum Glutamate Oxaloacetate Transaminase (SGOT), Serum Glutamate Pyruvate Transaminase (SGPT) and total bilirubin = 2.5 x upper limit of normal (ULN). - Signed informed consent. - All patients must agree to use a highly effective method of contraception (including both female patients of child-bearing potential and male patients with child-bearing potential partners). Effective birth control includes: a) birth control pills, depo-progesterone, or an IUD PLUS one barrier method, or b) two barrier methods. Effective barrier methods are: male and female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm). For patients using hormonal contraceptive method, information about any interaction of MAD3100 with hormonal contraceptives is not known. Exclusion Criteria: - A co-morbid condition which, in the view of the Investigators, renders the patient at high risk from treatment complications. - A residual acute medical condition resulting from prior chemotherapy. - Received thalidomide, dexamethasone or corticosteroids, Rituxan® and Velcade® within 7 days prior to randomization. - Brain metastases or carcinomatous meningitis. - Active acute or chronic infection or anti-infective therapy within 1 week prior to randomization. - Fever (temperature = 38 degrees celsius). - Hypercalcemia (= 1mg/dl above the ULN). - Known to be HIV-positive. - Pregnant and nursing females. - Patient unwilling to implement adequate birth control (including both female patients of child-bearing potential and male patients with child-bearing potential partners). - Patients who previously received experimental therapy within 4 weeks of randomization or who are currently enrolled in another experimental protocol during the Mobilization phase. - Patients who have failed previous collection attempt within 7 days or less from randomization. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Genzyme, a Sanofi Company |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine if patients reach a target of = 2x10^6 CD34+ cells/kg within 2 days of apheresis in Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) patients who are proven poor mobilizer. | after last apheresis | No | |
Secondary | To examine and compare the safety of both mobilization regimens, G-CSF plus AMD3100(240µg/kg) and G-CSF plus placebo in NHL, MM and HD patients. | After each dose of AMD3100 | Yes | |
Secondary | To measure the daily and total number of CD34+ cells harvested during apheresis. | After each dose of AMD3100 | No | |
Secondary | To measure the number of days of apheresis needed to harvest = 2x10^6 CD34+ cells/kg. | After each dose of AMD3100 transplantation and engraftment | No | |
Secondary | To measure the number of days of apheresis needed to harvest = 5x10^6 CD34+ cells/kg. | After each dose of AMD3100, transplantation and engraftment | No | |
Secondary | To determine the times of platelet (PLT) and polymorphonuclear leukocyte (PMN) engraftment. | After each dose of AMD3100, transplantation and engraftment | No | |
Secondary | To evaluate the durability of engraftment. | After each dose of AMD3100, transplantation and engraftment | No | |
Secondary | To determine if patient reach the Optimum Target of 5x10^6 CD34+ cells/kg within 4 days of apheresis. | After each dose of AMD3100, transplantation and engraftment | No | |
Secondary | To determine if NHL tumor cells are mobilized after either G-CSF mobilization of AMD3100 administration | After G-CSF mobilization period and after each dose of AMD3100 | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |